Screening for Chemotherapy Induced Peripheral Neuropathy
|
|
- Ursula Perry
- 5 years ago
- Views:
Transcription
1 Screening for Chemotherapy Induced Peripheral Neuropathy Elizabeth McGrath DNP, APRN, AGACNP BC, AOCNP, ACHPN Lara Ronan MD Victoria Lawson MD Lynsey Teulings MS, APRN Michaela Rowland MS, APRN, AOCNP
2 Defined as the presence of signs or symptoms of peripheral nerve dysfunction, as a consequence of damage to the peripheral or autonomic nervous system caused by chemotherapeutic agents CIPN
3 Background CIPN is a common treatment related side effect It has the potential to result in chemotherapy dose reductions and/or early discontinuation. The overall incidence of CIPN is ~38% in patients treated with multiple agents The proportion of cancer patients who experience neuropathic pain at some point in their survivorship ranges from 40% to 70% This percentage varies depending on regimens, duration of exposure and assessment methods.
4 Background Chemotherapy combinations with higher incidences include those that involve platinum drugs, vinca alkaloids, bortezomib and/or taxanes May begin weeks to months after initiation of therapy Often presents with a sensory neuropathy, including paresthesia's and pain Symptoms may resolve after completion of treatment but are often only partially reversible, and can remain for years
5 Background Research demonstrates learning about CIPN before chemotherapy was associated with a lower chance of severe CIPN Having healthcare providers ask about symptoms was linked with a greater chance of moderate vs severe CIPN (28% vs 17%) DuetolackofevidenceforeffectivemanagementofCIPN,regular assessment of neurological function is recommended. However no standardized measurement for CIPN exists and general agreement regarding the best way to assess and grade CIPN has not yet been reached
6 CIPN American Society of Clinical Oncology (ASCO) guidelines for the Prevention and Management of CIPN There are no established agents recommended for the prevention of CIPN in cancer patients undergoing treatment with neurotoxic agents. This is based on the paucity of high quality, consistent evidence and a balance of benefits versus harms.
7 CIPN Due to the lack of evidence for effective management of neurotoxicity, regular assessment of neurological function is recommended for patients receiving neurotoxic agents
8 CIPN Process Improvement OBJECTIVES Phase 1 Aim of the project was to evaluate the feasibility of integration of EBP assessment of CIPN into practice, and implement strategies to improve compliance with acceptable practice
9 Quality Improvement
10 CIPN Process Improvement Goals Develop and pilot a standardized process to identify cancer patients at risk for CIPN APRN conduct initial education session to include discussion of the potential for CIPN Conduct regular assessment & re assessment utilizing an evidencedbased assessment tool
11
12 Initial audit of 20 charts was done to investigate occurrence of discussion of CIPN by providers before and during chemotherapy INITIAL DISCUSSION OF CIPN 20 6 NP MD
13 Initial audit of 20 charts was done to investigate occurrence of discussion of CIPN by providers before and during chemotherapy
14 CIPN A literature search was done to select an evidenced based screening tool
15
16 EORTC QOL- CIPN 20 During the past week : Not at All A Little Quite a Bit 45 Did you have difficulty climbing stairs or getting up out of a chair because of weakness in your legs? Were you dizzy when standing up from a sitting or lying position? Did you have blurred vision? Did you have difficulty hearing? Please answer the following question only if you drive a car 49 Did you have difficulty using the pedals? Please answer the following question only if you are a man 50 Did you have difficulty getting or maintaining an erection? Please indicate how long it took you to fill out this questionnaire Minutes
17
18 CIPN CTCAE Grading
19 CIPN Initially data was collected on patients diagnosed with breast cancer Subsequently expanded to include colon and head and neck cancer patients Goal: to screen patients prior to treatment, mid cycle and posttreatment
20 REDCap Data collection instrument Total (N) 36 Total (N) 36 Total (N) 36 Missing Min Max Mean St Dev 0 (0.0%) Missing Min Max Mean St Dev Motor Score Sum Percentile Sensory Score Sum Percentile (0.0%) Missing Min Max Mean St Dev Autonomic Score Sum Percentile (0.0%) Please indicate how long it took you to complete the questionnaire (minutes) Total (N) 16 Missing Min Max Mean St Dev Sum Percentile (55.6%)
21 CIPN Results The patient time to complete survey is brief: 2 5 minutes Only one patient refused to complete the survey APRN s felt screening for CIPN did not significantly interrupt the flow of care
22 CIPN Results Before chemotherapy (25, 69.4%) Mid regimen (8, 22.2%) After Chemotherapy (3, 8.3%)
23 CIPN Conclusions The project demonstrates screening for CIPN can be easily accomplished by APRN s in the routine care of patients receiving chemotherapy
24 CIPN Phase 2 Educate APRN staff and expand screening to include assessment of all patients at risk of CIPN Expand assessment of chemotherapy induced peripheral neuropathy (CIPN) using a combination of subjective and objective measures (TNS Score) Develop CIPN patient education material Develop a process to ensure screening is done at the proper intervals Link CIPN screening to the computerized chemotherapy order set to ensure screening Develop a process for referral to specialty care when clinically significant CIPN is identified
25 CIPN References Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0, June 2010, National Institutes of Health, National Cancer Institute. Available at: _QuickReference_5x7.pdf (Accessed March 21, 2017) Lavoie Smith, E.M., Barton, D.L., Qin, R. et al. Qual Life Res (2013) 22: doi: /s Postma, T. J., Aaronson, N. K., Heimans, J. J., Muller, M. J., Hildebrand, J. G., Delattre, J. Y.,... Lucey, R. (2005). The development of an EORTC quality of life questionnaire to assess chemotherapy induced peripheral neuropathy: The QLQ CIPN20. European Journal of Cancer, 41(8), doi: Smith, M.L., White, C. B., Railey, E., Bellucci, R. and Thompson, C. Do informed patients have different CIPN outcomes? Results of a research advocacy network survey. Journal of Clinical Oncology :7_suppl, Smith TJ, Temin S, Alesi ER, et al. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. J Clin Oncol. 2012;30:880 7
1/21/14. Barriers to Assessment and Management of Chemotherapy- Induced Peripheral Neuropathy. Conflicts of Interest. Learning Objective
Barriers to Assessment and Management of Chemotherapy- Induced Peripheral Neuropathy Connie Visovsky, PhD, RN, ACNP-BC Associate Dean University of South Florida College of Nursing Conflicts of Interest
More informationChemotherapy-Induced Peripheral Neuropathy (CIPN) Measurement Approaches
Chemotherapy-Induced Peripheral Neuropathy (CIPN) Measurement Approaches Ellen Lavoie Smith PhD, APRN, AOCN, FAAN Associate Professor PhD Program Director University of Michigan School of Nursing Faculty
More informationWhat is the audience using for prevention of FOLFOX CIPN. What is the audience using for prevention of FOLFOX CIPN. Topics
Potentially Effective Therapies for FOLFOX-Induced Peripheral Neuropathy What is the audience using for prevention of FOLFOX CIPN Charles Loprinzi, MD cloprinzi@mayo.edu CP1347589-1 What is the audience
More informationTHE ROLE OF HIGH FREQUENCY ELECTRICAL STIMULATION IN THE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY POPULATION: A CASE SERIES
THE ROLE OF HIGH FREQUENCY ELECTRICAL STIMULATION IN THE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY POPULATION: A CASE SERIES Kathleen Fortier, PT, DPT, MBA Background Chemotherapy induced peripheral neuropathy
More informationQuality ID #457 (NQF 0216): Proportion Admitted to Hospice for less than 3 days- National Quality Strategy Domain: Effective Clinical Care
Quality ID #457 (NQF 0216): Proportion Admitted to Hospice for less than 3 days- National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE:
More informationClinician-reported Sign Outcome Measures of CIPN
Clinician-reported Sign Outcome Measures of CIPN A. Gordon Smith, MD FAAN Professor and Vice Chair of Neurology Chief, Division of Neuromuscular Medicine University of Utah School of Medicine Examination/Sign
More informationCHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY
CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY LONG-TERM OUTCOMES OF PACLITAXEL- INDUCED PERIPHERAL NEUROPATHY FOR CANCER SURVIVORS Hannah Timmins Faculty Disclosure x No, nothing to disclose Yes, please specify:
More informationObjectives for Instrument Validation
Validation of the Patient Neurotoxicity Questionnaire () During Taxane Chemotherapy in a Phase III Randomized Trial in Patients with Breast Cancer: N-SAS BC 02 Kojiro Shimozuma, MD, PhD 1,2, Yasuo Ohashi,
More informationMolassiotis et al. BMC Cancer (2019) 19:132
Molassiotis et al. BMC Cancer (2019) 19:132 https://doi.org/10.1186/s12885-019-5302-4 RESEARCH ARTICLE Are we mis-estimating chemotherapyinduced peripheral neuropathy? Analysis of assessment methodologies
More informationChemotherapy-Induced Peripheral Neurotoxicity: A Critical Analysis
Chemotherapy-Induced Peripheral Neurotoxicity: A Critical Analysis Susanna B. Park, PhD 1,2 *; David Goldstein, FRACP 3 ; Arun V. Krishnan, FRACP, PhD 4 ; Cindy S-Y Lin, PhD 5 ; Michael L. Friedlander,
More informationStudy of Oxaliplatin-based Chemotherapy-Induced Neurotoxicity in Colorectal Cancer Thai Patients
Original Article Mahidol University Journal of Pharmaceutical Sciences 2013; 40 (4), 8-16 Study of Oxaliplatin-based Chemotherapy-Induced Neurotoxicity in Colorectal Cancer Thai Patients J. Wutthikonsammakit,
More informationChemotherapy-Induced Peripheral Neuropathy in Egyptian Patients: Single Institution Retrospective Analysis
DOI:10.22034/APJCP.2018.19.8.2223 RESEARCH ARTICLE Editorial Process: Submission:02/05/2018 Acceptance:07/16/2018 in Egyptian Patients: Single Institution Retrospective Analysis Ahmed Gaballah*, Amr Shafik,
More informationOriginal Article. Mahmoud A. Ellithy 1, Lamia Elwakil 2, Mona Schaalan 3, Yomna A. El Hossamy 3
Original Article Research in Oncology 2018; Vol. 14, No. 2: 53-58. DOI: 10.21608/resoncol.2018.3375.1055 Impact of Exogenous Neurotropic Factor Administration on Occurrence and Severity of Paclitaxel-Induced
More information3/5/2018 CANCER ASSOCIATED FATIGUE & PAIN OBJECTIVES CHRONIC PAIN ACUTE PAIN PAIN SCALES
OBJECTIVES CANCER ASSOCIATED FATIGUE & PAIN SCOT M. SAWYER, PT, DPT BOARD CERTIFIED ELECTROPHYSIOLOGY CLINICAL SPECIALIST EMAIL: SAWYER@CAMPBELL.EDU Recognize the multi-factorial pain response cancer survivors
More informationImproving the Survivorship of Older Adults with Cancer Using Geriatric Assessment
Improving the Survivorship of Older Adults with Cancer Using Geriatric Assessment Deborah Bacon, RN,BSN Geriatric Oncology Clinical Nurse Coordinator James P Wilmot Cancer Institute Outline Geriatric assessment
More informationVincristine-Induced Toxicities Secondary to Azole Antifungal Therapy in Patients with Hematologic Malignancies
Vincristine-Induced Toxicities Secondary to Azole Antifungal Therapy in Patients with Hematologic Malignancies Kara E. Loth, PharmD PGY2 Oncology Resident Wake Forest University Baptist Medical Center
More informationSupportive Care makes excellent cancer care possible
Supportive Care makes excellent cancer care possible Irma Verdonck-de Leeuw With many thanks to Age Schultz and Dorothy M Keefe Supportive Care in Cancer The prevention & management of the adverse effects
More informationPrevention and screening of long term side effects. Lena Specht MD DMSc Professor of Oncology Rigshospitalet, University of Copenhagen Denmark
Prevention and screening of long term side effects Lena Specht MD DMSc Professor of Oncology Rigshospitalet, University of Copenhagen Denmark Disclosures Member of Advisory Board and Principal Investigator,
More informationJoint Session with ACOFP and Cancer Treatment Centers of America (CTCA): Cancer as a Chronic Illness. Kevin F. Tulipana, DO
Joint Session with ACOFP and Cancer Treatment Centers of America (CTCA): Cancer as a Chronic Illness Kevin F. Tulipana, DO Cancer As A Chronic Illness Kevin Tulipana, DO Hospital Medicine Cancer Treatment
More informationSurvivorship: Lifestyle Modifications of Diet and Exercise
Survivorship: Lifestyle Modifications of Diet and Exercise Alice S. Ryan, PhD Professor Division of Gerontology and Geriatric Medicine University of Maryland School of Medicine VA Senior Research Career
More informationEfficacy and safety of duloxetine in Chinese breast cancer patients with paclitaxel-induced peripheral neuropathy
Original Article Efficacy and safety of duloxetine in Chinese breast cancer patients with paclitaxel-induced peripheral neuropathy Jiani Wang, Qing Li, Binghe Xu, Tongtong Zhang, Shanshan Chen, Yang Luo
More informationGabapentinoid use for CIPN: The Good And The Bad. Charles Loprinzi MD Regis Professor of Breast Cancer Research.
Gabapentinoid use for CIPN: The Good And The Bad Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu Potential COI PledPharma AB re CIPN I d like some audience input regarding
More informationSymposium 2: The Future for Palliative Oncology
Symposium 2: The Future for Palliative Oncology 2-5 Additional Comment Palliative Oncology: Elimination of inconsistencies in palliative care and clinical oncology Higashi Sapporo Hospital Takeshi TERUI,
More informationCancer Survivorship NEURO-ONCOLOGY PATIENT SURVIVORSHIP PLAN. Resources and Tools for the Multidisciplinary Team
NEURO-ONCOLOGY PATIENT SURVIVORSHIP PLAN Cancer Survivorship Resources and Tools for the Multidisciplinary Team Your survivorship care plan is a summary of your tumor treatments and recommendations for
More informationObjectives. Conflict of Interest Disclosure. Author Conflict of Interest: The Next Hurdle for Cancer Survivors: Who will manage their Pain?
The Next Hurdle for Cancer Survivors: Who will manage their Pain? Linda Vanni, MSN, RN-BC, ACNS-BC, NP Nurse Practitioner, Pain Management Providence Hospital Southfield, MI Conflict of Interest Disclosure
More informationMultifactorial risk assessments and evidence-based interventions to address falls in primary care. Objectives. Importance
Multifactorial risk assessments and evidence-based interventions to address falls in primary care Sarah Ross, DO, MS Assistant Professor Internal Medicine, Geriatrics Nicoleta Bugnariu, PT, PhD Associate
More informationPrevalence of vincristine induced-peripheral neuropathy among Sudanese cancer patients
J Young Pharm, 2016; 8(3): 239-243 A multifaceted peer reviewed journal in the field of Pharmacy www.jyoungpharm.org www.phcog.net Original Article Prevalence of vincristine induced-peripheral neuropathy
More informationEvaluating the Total Costs of Chemotherapy-Induced Toxicity: Results from a Pilot Study with Ovarian Cancer Patients
Evaluating the Total Costs of Chemotherapy-Induced Toxicity: Results from a Pilot Study with Ovarian Cancer Patients ELIZABETH A. CALHOUN, CHIH-HUNG CHANG, EMILY E. WELSHMAN, DAVID A. FISHMAN, JOHN R.
More informationDiagnosis and Treatment of Neuropathy Post Chemotherapy in Three Health Care Systems
Diagnosis and Treatment of Neuropathy Post Chemotherapy in Three Health Care Systems HCSRN 2019 Conference April 10, 2019 Kaiser Permanente Research Peripheral neuropathy is a common side effect of neurotoxic
More informationAssessment of chemotherapy-induced peripheral neuropathy using the LDI FLARE technique: a novel technique to detect neural small fiber dysfunction
Assessment of chemotherapy-induced peripheral neuropathy using the LDI FLARE technique: a novel technique to detect neural small fiber dysfunction Sanjeev Sharma 1, Ramachandran Venkitaraman 2, Prashanth
More informationJCN Open Access INTRODUCTION ORIGINAL ARTICLE
JCN Open Access pissn 1738-6586 / eissn 2005-5013 / J Clin Neurol 2018;14(1):81-89 / https://doi.org/.3988/jcn.2018.14.1.81 ORIGINAL ARTICLE A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy
More informationThe QLQ-C30 cut-off project - Symptom screening with the EORTC quality of life scales
The QLQ-C30 cut-off project - Symptom screening with the EORTC quality of life scales Johannes Giesinger Division of Psychosocial Research and Epidemiology The Netherlands Cancer Institute Amsterdam The
More informationASCO Quality Oncology Practice Initiative (QOPI): Implications For A Rapid Learning System For Cancer
ASCO Quality Oncology Practice Initiative (QOPI): Implications For A Rapid Learning System For Cancer Joseph Jacobson, MD Chair, QOPI Steering Committee Salem MA October 6, 2009 American Society of Clinical
More informationAdaptation of Survivorship Care Plans in the Age of the EMR Challenges & Practical Solutions
Adaptation of Survivorship Care Plans in the Age of the EMR Challenges & Practical Solutions Elizabeth McGrath, DNP, APRN Darcy Kreis MS, RN Norris Cotton Cancer Center Dartmouth Hitchcock Medical Center
More information10/10/17. Disclosure. Feel the Burn. Chemotherapy- Induced Neuropathic Pain: Victories & Defeats
Chemotherapy- Induced Neuropathic Pain: Victories & Defeats W. Clay Jackson, MD, DipTh UTHSC Palliative Medicine @mydocjackson @aapainmanage Disclosure I report that I have investments in Aspire Healthcare.
More informationInternational Symposium on Supportive Care in Cancer, MASCC/ISOO 2013, Berlin, Germany. What was hot at MASCC/ISOO Annual Meeting this year?
International Symposium on Supportive Care in Cancer, MASCC/ISOO 2013, Berlin, Germany What was hot at MASCC/ISOO Annual Meeting this year? Supportive Care Makes Excellent Cancer Care Possible. This slogan
More informationTreating Non-painful Chemotherapy-induced Peripheral Neuropathy (CIPN): On Pins and Needles
Treating Non-painful Chemotherapy-induced Peripheral Neuropathy (CIPN): On Pins and Needles Adam Mah, BSc (Pharm), 2018 ACPR Candidate LMPS Adult Program August 30 th, 2017 1 Learning Objectives Be able
More informationPain Management Questionnaire
In order to make the most of your visit, we require this form to be completed to the best of your ability and sent to the Pain Management Clinic a copy should be shared with your Primary Care Provider
More informationSymptom Control During Chemotherapy (SCDC) MN Community Measurement
Symptom Control During Chemotherapy (SCDC) MN Community Measurement MN Community Measurement Nonprofit health care quality improvement and reporting organization Specialize in developing, collecting, analyzing
More information4/12/2018. Disclosure Statement of Financial Interest
Consultant/Over Prescribing Team 4/12/2018 Tennessee Chronic Pain Guidelines and Controlled Substance Efforts Symposia Linda Johnson, DNP APRN Consultant/Over Prescribing Team Disclosure Statement of Financial
More informationONCOLOGY NURSING SOCIETY RESEARCH AGENDA. M. Tish Knobf, PhD, RN, AOCN, FAAN ONS Research Agenda Team Leader
ONCOLOGY NURSING SOCIETY 2014 2018 RESEARCH AGENDA M. Tish Knobf, PhD, RN, AOCN, FAAN ONS Research Agenda Team Leader Content Leaders Mary E. Cooley, PhD, RN, FAAN Sonia Duffy, PhD, RN, FAAN Ardith Doorenbos,
More informationPeripheral neuropathy
Freephone helpline 0808 808 5555 information@lymphoma-action.org.uk www.lymphoma-action.org.uk Peripheral neuropathy Peripheral neuropathy is damage to the nerves of your peripheral nervous system (network
More informationDevelopment and pilot testing of a comprehensive support package for bowel cancer survivors
Development and pilot testing of a comprehensive support package for bowel cancer survivors Michael Jefford, Carl Baravelli, Megan Rogers, Penelope Schofield, Kerryann Lotfi-Jam, Meinir Krishnasamy, Carmel
More informationQUALITY OF LIFE IN CANCER CLINICAL TRIALS A Practical Guide For. Research Staff
QUALITY OF LIFE IN CANCER CLINICAL TRIALS A Practical Guide For Research Staff Contents What is Quality of Life?.. 1 QOL in Cancer Trials. 2 How is QOL Measured?....3 EORTC Questionnaires.....4 FACIT Questionnaires..
More informationCISPLATIN Chemo-radiation regimen Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol CISPLATIN Chemo-radiation regimen Gynaecological Cancer PROCTOCOL REF: MPHAGYNCIX (Version No: 1.0) Approved for use in: Locally advanced cervical cancer (adjuvant/curative)
More informationReview. Grading of chemotherapy-induced peripheral neuropathy. T. J. Postma & J. J. Heimans
Annals of Oncology 11: 509-513. 2000. 2000 Khmer Academic Publishers Printed in the Netherlands Review Grading of chemotherapy-induced peripheral neuropathy T. J. Postma & J. J. Heimans Department of Neurology,
More informationMEDICARE ANNUAL WELLNESS VISIT QUESTIONNAIRE
PATIENT NAME: Date of Birth: MEDICARE ANNUAL WELLNESS VISIT QUESTIONNAIRE Today s Date: The Annual Wellness Visit is for preventative health and provided by Medicare. This is not a visit to evaluate new
More informationThe New Role of Cancer Patient Engagement in Value Based Models
Mini Summit XIX: Case Studies in Specialty Medical Homes: How to Design APMs to Support Patients with Serious Health Conditions that Cannot be Managed by a PCP Ray Page, DO PhD The New Role of Cancer Patient
More informationcontinuing education CIPN: Treatment preservation and prevention are the goals Colleen H. Erb, MSN, ACNP-BC, AOCNP
continuing education educational objectives After participating in this activity, clinicians should be better able to Determine three of the most common causative agents for chemotherapy-induced peripheral
More informationOncology Management at HAP. John Calabria, DO, Medical Director
Oncology Management at HAP John Calabria, DO, Medical Director Agenda Rising Cost of Health Care Ways of Managing Oncology Cost Pathways Update Where do we go from here? The Cost of Cancer Source: National
More informationPatient Perceptions Associated With Chemotherapy-Induced Peripheral Neuropathy
This material is protected by U.S. copyright law. To purchase quantity reprints, e-mail reprints@ons.org. For permission to reproduce multiple copies, e-mail pubpermissions@ons.org. Online Exclusive Journal
More informationSTAYING FIT WITH KIDNEY DISEASE
STAYING FIT WITH KIDNEY DISEASE www.kidney.org Introduction Regular exercise is important for everyone and that includes people with kidney disease. Regular exercise will help you feel better, stronger,
More informationPharmaco-epidemiological outcome research
Pharmaco-epidemiological outcome research Using the PHARMO-Eindhoven Cancer Registry linkage Lonneke van de Poll-Franse Professor of Cancer Epidemiology and Survivorship, Tilburg University & Head department
More informationProcarbazine Lomustine and VinCRIStine (PCV) Therapy INDICATIONS FOR USE:
Procarbazine Lomustine and VinCRIStine (PCV) Therapy INDICATIONS FOR USE: INDICATION ICD10 Protocol Code Adjuvant treatment of Grade II glioma administered after C71 00379a radiotherapy Palliative treatment
More information2012 AAHPM & HPNA Annual Assembly
in the Last 2 Weeks of Life: When is it Appropriate? When is it Not Appropriate? Disclosure No relevant financial relationships to disclose AAHPM SIG Presentation Participants Eric Prommer, MD, FAAHPM
More informationThe Integration of Palliative Care into Standard Oncology Care. American Society of Clinical Oncology Provisional Clinical Opinion
The Integration of Palliative Care into Standard Oncology Care American Society of Clinical Oncology Provisional Clinical Opinion The Provisional Clinical Opinion Based on strong evidence from a phase
More informationPRE-VISIT QUESTIONNAIRE FOR NEW PATIENTS
UF Health Senior Care PO Box 100383 Gainesville, FL 32608 352-265-0615 Fax 352-294-5803 PRE-VISIT QUESTIONNAIRE FOR NEW PATIENTS Please complete this questionnaire at home and bring it with you to the
More informationCrystal T. Pike, 1 Howard G. Birnbaum, 1 Catherine E. Muehlenbein, 2 Gerhardt M. Pohl, 2 and Ronald B. Natale Introduction
Chemotherapy Research and Practice Volume 2012, Article ID 913848, 10 pages doi:10.1155/2012/913848 Research Article Healthcare Costs and Workloss Burden of Patients with Chemotherapy-Associated Peripheral
More informationBeyond the Break. After Breast Cancer: Osteoporosis in Survivorship. Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO
Beyond the Break After Breast Cancer: Osteoporosis in Survivorship Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO Disclosures No disclosures Osteoporosis in Breast Cancer Survivorship
More informationSystemic management of pancreatic cancer: Supportive care
Systemic management of pancreatic cancer: Supportive care Snežana Bošnjak @bosnjaksupport Institute for Oncology and Radiology of Serbia Serbia, Belgrade Supportive Care in Cancer The prevention & management
More informationHigh-dose 8% capsaicin patch in treatment of chemotherapyinduced peripheral neuropathy: single-center experience
Med Oncol (2017) 34:162 DOI 10.1007/s12032-017-1015-1 ORIGINAL PAPER High-dose 8% capsaicin patch in treatment of chemotherapyinduced peripheral neuropathy: single-center experience Iwona Filipczak-Bryniarska
More information2/6/ Allina Health System. Disclosure. Objectives
Survivorship Marketing Care for Update Breast Cancer Patients November February 26, 62013 th, 2016 Sarah Jax, MA, APRN, AOCNP Minnesota Oncology Disclosure There are no conflicts of interest or relevant
More informationERN services: A Patient Case Study. Matt Johnson, EURORDIS Potential ERN Services Second Workshop, PWC, Brussels 24 May 2016
ERN services: A Patient Case Study Matt Johnson, EURORDIS Potential ERN Services Second Workshop, PWC, Brussels 24 May 2016 1 Collective knowledge and expertise A European Reference Network is more than
More informationPlease complete ALL 6 pages of the form in blue/black ink. Patient Acct # Provider # BMI # Height Weight
Please complete ALL 6 pages of the form in blue/black ink. Patient Acct # Provider # BMI # Height Weight f-25-n (08-07-13) ( 11-02-12) 0 10 Spine Questionnaire (continued) OFFICE USE ONLY Patient Acct
More informationQuality of Life assessment: A perspective from The EORTC
Quality of Life assessment: A perspective from The EORTC Presentation to the European Commission Iniciative in Breast Cancer meeting Andrew Bottomley, PhD Assistant Director, Head of the QOL Department
More informationNPAC+PERT+TRAS Regimen
Regimen Monograph Regimen Name Drug Regimen Cycle Frequency Premedication and Supportive Measures Dose Modifications Adverse Effects Interactions Drug Administration and Special Precautions Recommended
More informationAssessment Tools for Peripheral Neuropathy in Pediatric Oncology: A Systematic Review From the Children s Oncology Group
762705JPOXXX10.1177/1043454218762705Journal of Pediatric Oncology NursingSmolik et al. research-article2018 Article Assessment Tools for Peripheral Neuropathy in Pediatric Oncology: A Systematic Review
More informationStroke Impact Scale VERSION 3.0
Stroke Impact Scale VERSION 3.0 The purpose of this questionnaire is to evaluate how stroke has impacted your health and life. We want to know from YOUR POINT OF VIEW how stroke has affected you. We will
More informationPHYSICAL RESIDUAL FUNCTIONAL CAPACITY QUESTIONNAIRE
PHYSICAL RESIDUAL FUNCTIONAL CAPACITY QUESTIONNAIRE To: Re: SS: The Social Security Administration needs your expert opinion of your patient s functional limitations caused by his/her impairments. You
More informationWhat makes Oncology special? Johanna MURSIC, Indication Programmer PhUSE congress Budapest, October 15 th 2012
What makes Oncology special? Johanna MURSIC, Indication Programmer PhUSE congress Budapest, October 15 th 2012 Disclaimer The opinions expressed in this presentation and on the following slides are solely
More informationNCCN Task Force Report: Management of
S-1 NCCN Task Force Report: Management of Neuropathy in Cancer Michael D. Stubblefield, MD; Harold J. Burstein, MD, PhD; Allen W. Burton, MD; Christian M. Custodio, MD; Gary E. Deng, MD, PhD; Maria Ho,
More informationInaugural Guildford Supportive Care in Cancer Course
Inaugural Guildford Supportive Care in Cancer Course SUPPORTIVE CARE OVERVIEW Declan Walsh 4 th November 2015 A BRIEF HISTORY OF MEDICINE 2000 BC HERE, EAT THIS ROOT 1000 AD THAT ROOT IS HEATHEN, SAY THIS
More informationElisabetta Munzone, MD Division of Medical Senology, European Institute of Oncology
Preventing chemotherapy-induced alopecia by scalp cooling: Preliminary data from a study on the efficacy and safety of DigniCap System in breast cancer patients Elisabetta Munzone, MD Division of Medical
More informationSummary of Results for Laypersons
What was the Study Called? Summary of Results for Laypersons A Phase 2a Enriched Enrollment Randomized Withdrawal Study to Assess Analgesic Efficacy and Safety of ASP8477 in Subjects with Peripheral Neuropathic
More informationThank You to Our Sponsors: Evaluations & CE Credits. Featured Speakers. Conflict of Interest & Disclosure Statements 10/18/2016
Thank You to Our Sponsors: University at Albany School of Public Health NYS Department of Health Conflict of Interest & Disclosure Statements The planners and presenters do not have any financial arrangements
More informationThe Psychosocial Services Coordinator
American American College College of of Surgeons 2013 Content 2014 Content cannot be be reproduced or or repurposed without written permission of of the the American College College of Surgeons. of Surgeons.
More informationHematology, Oncology & Blood & Marrow Transplant for NPs & PAs
PHARMACOLOGY CONTENT Hematology, Oncology & Blood & Marrow Transplant for NPs & PAs Select presentations will contain pharmacology content as noted in the program. Identified presentations represent approximately
More informationLead team presentation Eribulin for treating locally advanced or metastatic breast cancer after two or more prior chemotherapy regimens STA
For projector and public [noacic] Lead team presentation Eribulin for treating locally advanced or metastatic breast cancer after two or more prior chemotherapy regimens STA 1 st Appraisal Committee meeting
More informationOncologist. The. Assessment of Cancer-Related Neuropathy and Neuropathic Pain. The Oncologist 2010;15(suppl 2):
The Oncologist Assessment of Cancer-Related Neuropathy and Neuropathic Pain CHARLES S. CLEELAND, a JOHN T. FARRAR, b FREDERICK H. HAUSHEER c a University of Texas M.D. Anderson Cancer Center, Houston,
More informationCONFERENCE AGENDA (Subject to Change)
Thursday, August 9, 2018 7:00 am 5:30 pm Registration Desk Open 8:00 am 8:10 am Welcome and Announcements 8:10 am 9:00 am Best of ASCO Session 1 Genitourinary Cancer 9:00 am 9:50 am Best of ASCO Session
More informationPreventing and managing neurotoxicity by oncologists and neurologists
Preventing and managing neurotoxicity by oncologists and neurologists Thomas Hundsberger Department of Neurology and Department of Haematology/Oncology Cantonal hospital St. Gallen Switzerland Long-term
More information결장암환자에서보조적항암화학요법중삶의질변화
Korean Journal of Clinical Oncology 2016;12:60-66 http://dx.doi.org/10.14216/kjco.16010 pissn 1738-8082 eissn 2288-4084 Original Article 결장암환자에서보조적항암화학요법중삶의질변화 이서희 1, 이택구 1, 백무준 2, 김장진 1, 박성수 1, 이상전 1
More informationVinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trial
Original article Annals of Oncology 14: 699 703, 2003 DOI: 10.1093/annonc/mdg199 Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationPopulation-based quality of life research using the cancer registry. Lonneke van de Poll-Franse Professor of Cancer Epidemiology and Survivorship
Cancer Cancer Patient Registry Registry Population-based quality of life research using the cancer registry Lonneke van de Poll-Franse Professor of Cancer Epidemiology and Survivorship Eindhoven Cancer
More informationOriginal Article INTRODUCTION
Original Article The effect of pregabalin and duloxetine treatment on quality of life of breast cancer patients with taxane induced sensory neuropathy: A randomized clinical trial Razieh Avan 1,2, Ghasem
More informationOne Palliative Care Annual Report
One 203 Palliative Care Annual Report One In 202, ASCO released a provisional clinical opinion stating that concurrent palliative care should be considered early in the course of advanced or metastatic
More informationLocoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
More informationInfosheet. Peripheral neuropathy. What is peripheral neuropathy? The peripheral nervous system
Infosheet Peripheral neuropathy What is peripheral neuropathy? Peripheral neuropathy is the term used to describe damage to the nerves that make up the peripheral nervous system. In myeloma the nerves
More informationThe work of the QoL-Group at EORTC
The work of the QoL-Group at EORTC Francesca Martinelli, MSc EORTC HQ, Brussels, BE 8 th SPAEN Annual Conference February 2-4, 2018 Milan, IT World Cancer Day 2018 (Sunday) Quality of Life (QoL) has been
More informationINTERMEZZO ONCOQUEST: A TOUCH-SCREEN COMPUTER ASSISTED SYSTEM TO MONITOR HEALTH RELATED QUALITY OF LIFE VIA PATIENT REPORTED OUTCOME MEASURES
24 INTERMEZZO ONCOQUEST INTERMEZZO ONCOQUEST: A TOUCH-SCREEN COMPUTER ASSISTED SYSTEM TO MONITOR HEALTH RELATED QUALITY OF LIFE VIA PATIENT REPORTED OUTCOME MEASURES 26 INTERMEZZO In 2006, the Department
More informationpan-canadian Oncology Drug Review Final Economic Guidance Report Crizotinib (Xalkori) Resubmission for Advanced Non-Small Cell Lung Cancer
pan-canadian Oncology Drug Review Final Economic Guidance Report Crizotinib (Xalkori) Resubmission for Advanced Non-Small Cell Lung Cancer May 2, 2013 DISCLAIMER Not a Substitute for Professional Advice
More informationMeet the Professor Dosing and toxicity management
Meet the Professor Dosing and toxicity management Lodovico Balducci & Catherine Terret Mrs. Marie O. 78 years Right breast tumor : 50 mm, upper outer quadrant, Node: 0 Biopsy (9 Dec 2009) Invasive ductal
More informationLung Cancer Patient Outcomes
Lung Cancer Patient Outcomes Dr Neal Navani MA MSc PhD FRCP Consultant Respiratory Physician, UCLH Clinical Senior Lecturer, UCL Lead Clinician for Lung Cancer, UCLH Co-Clinical Lead, NLCA, Royal College
More informationResidual Functional Capacity Questionnaire CERVICAL SPINE
Residual Functional Capacity Questionnaire CERVICAL SPINE Patient: DOB: Physician completing this form: Please complete the following questions regarding this patient's impairments and attach all supporting
More informationTrialling computer touch-screen technology to assess psychological distress in patients with gynaecological cancer
Trialling computer touch-screen technology to assess psychological distress in patients with gynaecological cancer Georgia Halkett 1, Moyez Jiwa 2, Pauline Tanner 3, Céline Fournier 1, Paul Katris 4 1-WA
More informationPeripheral neuropathy
Peripheral neuropathy This Infosheet explains what the peripheral nervous system is, what peripheral neuropathy is, what causes it in AL amyloidosis patients, its symptoms and treatments and tips for self-management.
More informationEstablishing a Survivorship Program Within a Large Academic Medical Center
Establishing a Survivorship Program Within a Large Academic Medical Center Andrew J. Ward FNP-BC Surgical Oncology, The University of Tennessee Medical Center Disclosures I have no disclosures. Program
More informationORIGINAL ARTICLE. Keywords Breast cancer. Chemotherapy. Peripheral neuropathy. CIPN. Survivorship. Symptoms. Work. Perceived occupational function
Support Care Cancer (2016) 24:4779 4789 DOI 10.1007/s00520-016-3329-5 ORIGINAL ARTICLE Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work
More informationfrom 20 February 2014
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII - Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More information